Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B‐cell lymphoma could be valuable for predicting treatment outcome.

Detalles Bibliográficos
Autores principales: Nabe, Yoshimi, Kikuchi, Shohei, Kamihara, Yusuke, Wada, Akinori, Murakami, Jun, Sato, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365553/
https://www.ncbi.nlm.nih.gov/pubmed/34430019
http://dx.doi.org/10.1002/ccr3.4657
_version_ 1783738731495161856
author Nabe, Yoshimi
Kikuchi, Shohei
Kamihara, Yusuke
Wada, Akinori
Murakami, Jun
Sato, Tsutomu
author_facet Nabe, Yoshimi
Kikuchi, Shohei
Kamihara, Yusuke
Wada, Akinori
Murakami, Jun
Sato, Tsutomu
author_sort Nabe, Yoshimi
collection PubMed
description Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B‐cell lymphoma could be valuable for predicting treatment outcome.
format Online
Article
Text
id pubmed-8365553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83655532021-08-23 Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement Nabe, Yoshimi Kikuchi, Shohei Kamihara, Yusuke Wada, Akinori Murakami, Jun Sato, Tsutomu Clin Case Rep Case Report Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B‐cell lymphoma could be valuable for predicting treatment outcome. John Wiley and Sons Inc. 2021-08-16 /pmc/articles/PMC8365553/ /pubmed/34430019 http://dx.doi.org/10.1002/ccr3.4657 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Nabe, Yoshimi
Kikuchi, Shohei
Kamihara, Yusuke
Wada, Akinori
Murakami, Jun
Sato, Tsutomu
Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title_full Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title_fullStr Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title_full_unstemmed Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title_short Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
title_sort early complete response of primary bone marrow b‐cell lymphoma treated with rituximab‐based chop therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365553/
https://www.ncbi.nlm.nih.gov/pubmed/34430019
http://dx.doi.org/10.1002/ccr3.4657
work_keys_str_mv AT nabeyoshimi earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement
AT kikuchishohei earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement
AT kamiharayusuke earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement
AT wadaakinori earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement
AT murakamijun earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement
AT satotsutomu earlycompleteresponseofprimarybonemarrowbcelllymphomatreatedwithrituximabbasedchoptherapyassessedbyflowcytometryandimmunogloblinheavychainrearrangement

Ejemplares similares